• 제목/요약/키워드: virus clearance

검색결과 34건 처리시간 0.028초

Enhanced Virus Removal by Flocculation and Microfiltration

  • Han Binbing;Carlson Jonathan O.;Powers Scott M.;Wickramasinghe S. Ranil
    • Biotechnology and Bioprocess Engineering:BBE
    • /
    • 제7권1호
    • /
    • pp.6-9
    • /
    • 2002
  • In this work we have investigated the feasibility of virus clearance by flocculation and tangential flow microfiltration. Chinese hamster ovary cell feed streams were spiked with minute virus of mice and then flocculated using cationic polyelectrolytes prior to tangential flow microfiltration. Our results indicate that flocculation prior to microfiltration leads to more than 100 fold clearance of minute virus of mice particles in the permeate. Today, validation of virus clearance is a major concern in the manufacture of biopharmaceutical products. Frequently new unit operations are added simply to validate virus clearance thus increasing the manufacturing cost. The results obtained here suggest that virus clearance can be obtained during tangential flow microfiltration. Since tangential flow microfiltration is frequently used for bioreactor harvesting this could be a low cost method to validate virus clearance.

The Rate of Conversion from Immune-tolerant Phase to Early Immune-clearance Phase in Children with Chronic Hepatitis B Virus Infection

  • Hong, Suk Jin;Park, Hyo Jung;Chu, Mi Ae;Choi, Bong Seok;Choe, Byung-Ho
    • Pediatric Gastroenterology, Hepatology & Nutrition
    • /
    • 제17권1호
    • /
    • pp.41-46
    • /
    • 2014
  • Purpose: The spontaneous seroconversion rate of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) virus infection in children is lower than that in adults. However, few studies have investigated the rate of transition from the immune-tolerant to the early immune-clearance phase in children. Methods: From February 2000 to August 2011, we enrolled 133 children aged <18 years who had visited the Department of Pediatrics, Kyungpook National University Hospital. All subjects were in the immune-tolerant phase of HBeAg-positive CHB virus infection. The estimated transition rate into the early immune-clearance phase was calculated using the Kaplan-Meier method. Results: Among the 133 enrolled pediatric CHB virus infection patients in the HBeAg-positive immune-tolerant phase, only 21 children (15.8%) had converted to the early immune-clearance phase. The average age at entry into active hepatitis was $10.6{\pm}4.8$ years. The incidence of transition from the immune-tolerant to the early immune-clearance phase in these children was 1.7 episodes/100 patient-years. When analyzed by age, the estimated transition rate was 4.6%, 7.1%, and 28.0% for patients aged <6, 6-12, >12 years, respectively. Conclusion: In children with CHB virus infection, the estimated rate of entry into the early immune-clearance phase was 28.0% for patients aged 12-18 years, which was significantly higher than that observed for children aged <12 years (11.7%; p=0.001).

Association between Interferon-Inducible Protein 6 (IFI6) Polymorphisms and Hepatitis B Virus Clearance

  • Park, Geun-Hee;Kim, Kyoung-Yeon;Cho, Sung Won;Cheong, Jae Youn;Yu, Gyeong Im;Shin, Dong Hoon;Kwack, Kyu Bum
    • Genomics & Informatics
    • /
    • 제11권1호
    • /
    • pp.15-23
    • /
    • 2013
  • CD8+T cells are key factors mediating hepatitis B virus (HBV) clearance. However, these cells are killed through HBV-induced apoptosis during the antigen-presenting period in HBV-induced chronic liver disease (CLD) patients. Interferon-inducible protein 6 (IFI6) delays type I interferon-induced apoptosis in cells. We hypothesized that single nucleotide polymorphisms (SNPs) in the IFI6 could affect the chronicity of CLD. The present study included a discovery stage, in which 195 CLD patients, including chronic hepatitis B (HEP) and cirrhosis patients and 107 spontaneous recovery (SR) controls, were analyzed. The genotype distributions of rs2808426 (C > T) and rs10902662 (C > T) were significantly different between the SR and HEP groups (odds ratio [OR], 6.60; 95% confidence interval [CI], 1.64 to 26.52, p = 0.008 for both SNPs) and between the SR and CLD groups (OR, 4.38; 95% CI, 1.25 to 15.26; p = 0.021 and OR, 4.12; 95% CI, 1.18 to 14.44; p = 0.027, respectively). The distribution of diplotypes that contained these SNPs was significantly different between the SR and HEP groups (OR, 6.58; 95% CI, 1.63 to 25.59; p = 0.008 and OR, 0.15; 95% CI, 0.04 to 0.61; p = 0.008, respectively) and between the SR and CLD groups (OR, 4.38; 95% CI, 1.25 to 15.26; p = 0.021 and OR, 4.12; 95% CI, 1.18 to 14.44; p = 0.027, respectively). We were unable to replicate the association shown by secondary enrolled samples. A large-scale validation study should be performed to confirm the association between IFI6 and HBV clearance.

세포배양 유래 생물의약품 생산 공정에서 Minute Virus of Mice 안전성 검증을 위한 Real-Time PCR (Real-Time PCR for Validation of Minute Virus of Mice Safety during the Manufacture of Mammalian Cell Culture-Derived Biopharmaceuticals)

  • 이동혁;조항미;김현미;이정숙;김인섭
    • 한국미생물·생명공학회지
    • /
    • 제36권1호
    • /
    • pp.12-20
    • /
    • 2008
  • 세포배양 유래 생물의약품 생산 공정에서 다양한 바이러스가 오염된 사례가 있기 때문에 바이러스 안전성 검증이 필수적이다. MVM은 동물 세포주와 동물 세포 배양 공정에 오염되는 대표적인 바이러스이다. 세포배양 유래 생물의약품의 MVM 안전성을 확보하기 위해, 세포주, 원료물질, 제조공정, 완제품에서 MVM을 정량적으로 검출하고, 제조공정에서 MVM 제거 검증을 위한 시험법으로 활용이 가능한 real-time PCR 시험법을 확립하였다. MVM에 특이적인 primer를 선별하였으며, 형광염료 SYBR Green I을 사용하여 MVM DNA 정량 검출 시험법을 최적화하였다. 세포배양 법에 의한 감염역가와 비교한 결과 real-time PCR 민감도는 $6{\times}10^{-2}TCID_{50}/mL$이었다. 확립된 시험법의 신뢰성(reliability)을 보증하기 위해 시험법 검증을 실시한 결과 특이성(specificity)과 재현성(reproducibility)이 우수함을 확인하였다. 확립된 real-time PCR을 생물의약품 제조공정 검증에 적용할 수 있는지 확인하기 위하여 인위적으로 MVM을 오염시킨 CHO 세포에서 MVM검출 시험을 실시한 결과 MVM을 감염시킨 CHO 세포와 세포배양 상청액에서 MVM을 정량적으로 검출할 수 있었다. 또한 바이러스 필터 공정에서 MVM제거 효과를 감염역가 시험법과 비교 검증한 결과 더 높은 민감도로 빠른 시간에 동일한 결과를 얻을 수 있었다. 위와 같은 결과에서 확립된 MVM real-time PCR시험법은 생물의약품 안전성 보증을 위한 세포주 검증, 생물의약품 생산 공정 검증, 바이러스 제거 공정 검증 등에서 감염역가 시험법을 대신할 수 있는 신속하고, 특이성과 민감성이 우수한 시험법임을 확인하였다.

Immune-mediated Liver Injury in Hepatitis B Virus Infection

  • Oh, In Soo;Park, Su-Hyung
    • IMMUNE NETWORK
    • /
    • 제15권4호
    • /
    • pp.191-198
    • /
    • 2015
  • Hepatitis B virus (HBV) is responsible for approximately 350 million chronic infections worldwide and is a leading cause of broad-spectrum liver diseases such as hepatitis, cirrhosis and liver cancer. Although it has been well established that adaptive immunity plays a critical role in viral clearance, the pathogenetic mechanisms that cause liver damage during acute and chronic HBV infection remain largely known. This review describes our current knowledge of the immune-mediated pathogenesis of HBV infection and the role of immune cells in the liver injury during hepatitis B.

Association Analysis of SERPINB5 Polymorphisms with HBV Clearance and HCC Occurrence in a Korean Population

  • Kim, Ja-Son Y.;Park, Tae-Joon;Lee, Jin-Sol;Chun, Ji-Yong;Bae, Joon-Seol;Park, Byung-Lae;Cheong, Hyun-Sub;Lee, Hyo-Suk;Kim, Yoon-Jun;Shin, Hyoung-Doo
    • Genomics & Informatics
    • /
    • 제8권1호
    • /
    • pp.1-8
    • /
    • 2010
  • Serpin peptidase inhibitor, Clade B (ovalbumin), Member 5 (SERPINB5), also known as maspin, is a potent tumor suppressor gene. It has correlations with many tumor cells, from pancreas cancer to breast cancer, so it is possible that it may also affect liver cancer. There has also been a report that SERPINB12, a gene placed right next to SERPINB5, is expressed in liver. For this study, 32 polymorphisms were identified in SERPINB5 by direct DNA sequencing, and 11 of them were selected to be tested with a larger scale subjects. The association of the 11 SERPINB5 polymorphisms with Hepatitis B virus (HBV) clearance, hepatocellular carcinoma (HCC) occurrence and the onset age of HCC were analyzed. There were no significant associations found between 11 SERPINB5 polymorphisms and HBV clearance. In the case of HCC occurrence, one of the haplotypes (ht) showed association with HCC occurrence (OR=2.26, p=0.005, $P^{Cor}=0.05$), albeit with a low statistical power (40.8%) and haplotype frequency (0.052). Further study with a bigger sample size will be needed to clearly verify the association between ht5 and HCC occurrence.

Lack of Association of BIRC5 Polymorphisms with Clearance of HBV Infection and HCC Occurrence in a Korean Population

  • Lee, Jin-Sol;Kim, Jeong-Hyun;Park, Byung-Lae;Cheong, Hyun-Sub;Kim, Jason-Y.;Park, Tae-Joon;Chun, Ji-Yong;Bae, Joon-Seol;Lee, Hyo-Suk;Kim, Yoon-Jun;Shin, Hyoung-Doo
    • Genomics & Informatics
    • /
    • 제7권4호
    • /
    • pp.195-202
    • /
    • 2009
  • BIRC5 (Survivin) belongs to the inhibitor of apoptosis gene family. The BIRC5 protein inhibits caspases and consequently blocks apoptosis. Thus, BIRC5 contributes to the progression of cancer allowing for continued cell proliferation and survival. In this study, we identified eight sequence variants of BIRC5 through direct DNA sequencing. Among the eight single nucleotide polymorphisms (SNPs), six common variants with frequencies higher than 0.05 were selected for larger-scale genotyping (n=1,066). Results of the study did not show any association between the promoter region polymorphisms and the clearance of hepatitis B virus (HBV) infection and hepatocellular carcinoma (HCC) occurrence. This is in line with a previous study in which polymorphisms in the promoter region does not influence the function of BIRC5. Initially, we were able to detect a signal with the +9194A>G, which disappeared after multiple corrections but led to a change in amino acid. Similarly, we were also able to detect an association signal between two haplotypes (haplotype-2 and haplotype-5) on the onset age of HCC and/or HCC occurrence, but the signals also disappeared after multiple corrections. As a result, we concluded that there was no association between BIRC5 polymorphisms and the clearance HBV infection and/or HCC occurrence. However, our results might useful to future studies.

연속 유동 Ultraviolet-C 반응기(UVivatec)의 바이러스 불활화 효과 평가 (Evaluation of Viral Inactivation Efficacy of a Continuous Flow Ultraviolet-C Reactor (UVivatec))

  • 배정은;정은교;이재일;이정임;김인섭;김종수
    • 한국미생물·생명공학회지
    • /
    • 제37권4호
    • /
    • pp.377-382
    • /
    • 2009
  • 사람과 동물 유래의 혈장, 세포, 조직 등을 이용하여 생물의약품을 생산하기 위해서는 바이러스 안전성 확보가 필수적이다. 바이러스 안전성 보증을 위해 생물의약품 제조공정은 바이러스 불활화/제거 단계를 포함하여야 한다. 짧은 파장자외선(UVC) 조사는 바이러스 불활화 효과가 매우 높은 것으로 알려졌지만, UVC 조사로 인한 단백질의 변성과 대상 물질에 동일하게 조사를 할 수 있는 기계적 장치 개발의 어려움으로 인해 UVC 조사는 생물의약품 제조 공정에 사용되지 못했다. 최근에 이러한 결점을 해결한 연속 유동 UVC 반응기(UVivatec)가 개발되었다. UVivatec의 바이러스 불활화 효과 및 단백질 회수율을 검증하기 위해 단백질 의약품을 대상으로 적용가능성을 조사하였다. 최적화된 $3,000\;J/m^2$ 조사 공정에서 단백질의 회수율은 98%이상이었다. UVC 조사에 의한 human immunodeficiency virus(HIV), hepatitis A virus(HAV), bovine herpes virus(BHV), bovine viral diarrhea virus(BVDV), porcine parvovirus(PPV), bovine parvovirus(BPV), minute virus of mice(MVM), reovirus type 3(REO), bovine parainfluenza virus type 3(BPIV) 불활화 효과를 평가하였다. HAV, PPV, BPV, MVM, REO와 같은 비외피(nonenvelope) 바이러스는 $3,000\;J/m^2$ 조사량에 의해 검출한계 이하로 완벽하게 불활화되었다. HIV, BVDV, BPIV 같은 외피(envelope) 바이러스도 $3,000\;J/m^2$ 조사량에 의해 검출한계 이하로 완벽하게 불활화되었다. 또한 BHV도 매우 민감하게 불활화되었다. UVC 조사에 의한 각 바이러스들의 로그 감소율은 HIV는 ${\geq}3.89$, HAV는 ${\geq}5.27$, BHV는 5.29, BVDV는 ${\geq}5.96$, PPV는 ${\geq}4.37$, BPV는 ${\geq}3.55$, MVM은 ${\geq}3.51$, REO는 ${\geq}4.20$, BPIV는 ${\geq}4.15$이었다. 이와 같은 결과에서 UVivatec을 이용한 UVC 조사는 바이러스 불활화에 매우 효과적인 방법임을 확인하였다.

Analysis of Immune Responses Against Nucleocapsid Protein of the Hantaan Virus Elicited by Virus Infection or DNA Vaccination

  • Woo Gyu-Jin;Chun Eun-Young;Kim Keun Hee;Kim Wankee
    • Journal of Microbiology
    • /
    • 제43권6호
    • /
    • pp.537-545
    • /
    • 2005
  • Even though neutralizing antibodies against the Hantaan virus (HTNV) has been proven to be critical against viral infections, the cellular immune responses to HTNV are also assumed to be important for viral clearance. In this report, we have examined the cellular and humoral immune responses against the HTNV nucleocapsid protein (NP) elicited by virus infection or DNA vaccination. To examine the cellular immune response against HTNV NP, we used $H-2K^b$ restricted T-cell epitopes of NP. The NP-specific $CD8^+$ T cell response was analyzed using a $^{51}Cr-release$ assay, intracellular cytokine staining assay, enzyme-linked immunospot assay and tetramer binding assay in C57BL/6 mice infected with HTNV. Using these methods, we found that HTNV infection elicited a strong NP-specific $CD8^+$ T cell response at eight days after infection. We also found that several different methods to check the NP-specific $CD8^+$ T cell response showed a very high correlation among analysis. In the case of DNA vaccination by plasmid encoding nucleocapsid gene, the NP-specific antibody response was elicited $2\~4$ weeks after immunization and maximized at $6\~8$ weeks. NP-specific $CD8^+$ T cell response reached its peak 3 weeks after immunization. In a challenge test with the recombinant vaccinia virus expressing NP (rVV-HTNV-N), the rVV-HTNV-N titers in DNA vaccinated mice were decreased about 100-fold compared to the negative control mice.